MedTrace Logo

Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure.

NCT07319117 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-06

No results posted yet for this study

Summary

The proposed project will evaluate the synergistic effects of a nutritional formulation, 'Think Tank' on cognitive performance following exposure to a psychological and physical stressor. Adopting a double-blind repeated measures cross-over design, middle-aged females (40-60 years) will be recruited to take part in a two-stage research study that will examine whether the formulation enhances cognitive performance and subjective well-being following the challenge of a stressor, compared to placebo. Cognitive assessments will examine the impact of the nutritional formulation on working memory, sustained attention, cognitive flexibility and inhibitory control. The study will also assess physiological (heart rate, blood pressure and cortisol) and subjective (well-being, anxiety, positive and negative mood, stress) markers of stress reactivity. The study will also explore levels sleep quality, mental and physical fatigue, effort, productivity, and perceived impact of the intervention.

Conditions

  • Cognitive Assessment
  • Working Memory
  • Executive Function (Cognition)
  • Sustained Attention
  • Inhibitory Control
  • Cognitive Flexibility
  • Cortisol
  • Stress
  • Anxiety
  • Depression
  • Sleep Quality
  • Blood Pressure
  • Heart Rate
  • Mental Fatigue
  • Physical Fatigue
  • Productivity
  • Effort

Interventions

DIETARY_SUPPLEMENT

Skoshify 'Think Tank' Formulation

Each acute dose contains, Magnesium 105mg, Sodium 5mg, Creatine Monohydrate 2.5g, Magnesium Gluconate 2g, L-Tyrosine 500mg, Phosphatidylserine 20% powder 200mg, L-Theanine 200mg, Citicoline Sodium 125mg, Rhodiola Rosea Root Extract 100mg.

OTHER

Placebo

The placebo contains Maltodextrin from corn 1.5mg and Organic acacia gum powder 0.5g.

Sponsors & Collaborators

  • Sköshify™ Corporate HQ, 7045 Quiet Retreat Court, Niwot, CO 80503-7174

    collaborator UNKNOWN

  • Leeds Beckett University

    lead OTHER

Principal Investigators

  • Zoe K Kolokotroni, PhD · Leeds Beckett University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2026-08-01
Completion
2026-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07319117 on ClinicalTrials.gov